-
By Fierce Biotech - Jan 21, 2021
VERU TOUTS NOVEL BREAST CANCER TREATMENT STRATEGY AS DRUG NEARS PHASE 3
Veru touts novel breast cancer treatment strategy as drug nears phase 3 aliu Thu, 01/21/2021 - 07:46
Drugs, Drug, Cancer -
By Fierce Biotech - Jan 21, 2021
RALLYBIO HIRES TUCH FROM BMO TO LEAD CORPORATE DEVELOPMENT
Rallybio hires Tuch from BMO to lead corporate development ntaylor Thu, 01/21/2021 - 08:25
-
By Fierce Biotech - Jan 21, 2021
PLEXIUM BUMPS UP SERIES A BY $35M AS IT BATTLES RIVALS IN THE NEW PROTEIN-DEGRADATION SPACE
Plexium bumps up series A by $35M as it battles rivals in the new protein-degradation space badams Thu, 01/21/2021 - 08:32
Protein -
By Fierce Biotech - Jan 21, 2021
AFTER BAGGING YESCARTA EXEC AS CMO, T-CELL BIOTECH NEXIMMUNE FILES FOR $86M IPO
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO badams Thu, 01/21/2021 - 04:31
Biotech, BioTech -
By Fierce Biotech - Jan 21, 2021
SERVIER, MINA ALLY TO UPREGULATE NEUROLOGICAL DISORDER PROTEINS USING SMALL ACTIVATING RNAS
Servier, MiNA ally to upregulate neurological disorder proteins using small activating RNAs ntaylor Thu, 01/21/2021 - 07:51
Protein, Neurology -
By Fierce Biotech - Jan 20, 2021
IONIS AND UCSD TAKE AN ANTISENSE APPROACH TO FIGHTING TREATMENT-RESISTANT MULTIPLE MYELOMA
Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma arlene.weintraub Wed, 01/20/2021 - 09:32
-
By Fierce Biotech - Jan 20, 2021
BIDEN AND BIOTECH: SCIENCE FIRST
Biden and biotech: Science first badams Tue, 01/19/2021 - 04:19
Biotech, Science, BioTech -
By Fierce Biotech - Jan 20, 2021
TURNSTONE BUYS MYST TO ADD TUMOR-INFILTRATING LYMPHOCYTE ASSETS
Turnstone buys Myst to add tumor-infiltrating lymphocyte assets ntaylor Wed, 01/20/2021 - 08:07
-
By Fierce Biotech - Jan 20, 2021
ADAGENE PLANS $125M IPO TO GO AFTER CANCER NICHES TARGETED BY BMS AND PFIZER
Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer ntaylor Wed, 01/20/2021 - 08:52
Cancer -
By Fierce Biotech - Jan 20, 2021
ROLLER COASTER RIDE FOR VERASTEM CONTINUES AS 2 WEEKS INTO THE JOB, ITS CMO QUITS
Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits badams Wed, 01/20/2021 - 09:03
-
By Fierce Biotech - Jan 20, 2021
RIDE HEALTH GIVES PATIENTS A LIFT TO COVID-19 TREATMENT, VACCINE TRIALS
Ride Health gives patients a lift to COVID-19 treatment, vaccine trials chale Wed, 01/20/2021 - 09:16
Vaccine, Health, Vaccines -
By Fierce Biotech - Jan 20, 2021
GSK, GERMAN MERCK'S $4.2B BINTRAFUSP ALFA DRUG A BUST, FAILS TO BEAT KING KEYTRUDA IN LUNG CANCER
GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer badams Wed, 01/20/2021 - 09:28
Drugs, Drug, Cancer -
By Fierce Biotech - Jan 19, 2021
LILLY GIVES $60M TO MERUS, TIES IN $1.6B IN BIOBUCKS FOR NEXT-GEN CANCER RESEARCH PACT
Lilly gives $60M to Merus, ties in $1.6B in biobucks for next-gen cancer research pact badams Tue, 01/19/2021 - 07:44
Research, Cancer -
By Fierce Biotech - Jan 19, 2021
EX-GILEAD EXECS BAG $80M TO TRIAL DRUG LICENSED FROM MERCK KGAA
Ex-Gilead execs bag $80M to trial drug licensed from Merck KGaA ntaylor Tue, 01/19/2021 - 08:16
Drugs, Drug -
By Fierce Biotech - Jan 19, 2021
UNLEASHING THE CANCER-FIGHTING GENE TP53 IN LEUKEMIA WITH A NOVEL COMBINATION TREATMENT
Unleashing the cancer-fighting gene TP53 in leukemia with a novel combination treatment arlene.weintraub Tue, 01/19/2021 - 08:18
Genes, Gene, Cancer -
By Fierce Biotech - Jan 19, 2021
GILEAD'S KITE PHARMA UNIT NABS MARINCOLA TO HEAD UP ITS CELL THERAPY RESEARCH
Gilead's Kite Pharma unit nabs Marincola to head up its cell therapy research badams Tue, 01/19/2021 - 09:10
Therapies, Research, Pharma -
By Fierce Biotech - Jan 19, 2021
BIOHAVEN FLUNKS ALZHEIMER'S PHASE 2/3, TOUTS FAILED SUBGROUP AS SIGN OF EFFICACY
Biohaven flunks Alzheimer's phase 2/3, touts failed subgroup as sign of efficacy ntaylor Tue, 01/19/2021 - 06:20
-
By Fierce Biotech - Jan 15, 2021
NEXTCURE NABS NEXIMMUNE, CELGENE RESEARCH VET AS NEW CMO 6 MONTHS AFTER FORMER CMO QUIT
NextCure nabs NexImmune, Celgene research vet as new CMO 6 months after former CMO quit badams Fri, 01/15/2021 - 07:51
Research -
By Fierce Biotech - Jan 15, 2021
CHUTES & LADDERS-BRISTOL MYERS HEMATOLOGY CHIEF AHMED HITS EXIT
Chutes & Ladders-Bristol Myers hematology chief Ahmed hits exit fkansteiner Fri, 01/15/2021 - 01:15
-
By Fierce Biotech - Jan 15, 2021
HOW A GENE LINKED TO THE CIRCADIAN CLOCK COULD POINT TO NEW PROSTATE CANCER TREATMENTS
How a gene linked to the circadian clock could point to new prostate cancer treatments arlene.weintraub Fri, 01/15/2021 - 08:15
Cancer, Gene, Genes
-
The headlines of BioTech Mag
-
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
-
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
-
PacBio-Powered Analysis Indicates Methylation Makes TB Pathogen So Wily
Scientists have long struggled to explain the success of Mycobacterium tuberculosis in the face of effective therapeutics. Tuberculosis kills more than 1 million people...
-
Circular RNA circ 0032821 contributes to oxaliplatin resistance of gastric...
Abstract Objectives Chemoresistance is one of the major obstacles for gastric cancer treatment. Exosome-mediated transfer of circular RNAs is associated with the...
-
MiR-19a mitigates hypoxia/reoxygenation-induced injury by depressing CCL20...
Abstract Objective Myocardial infarction is a prevalent cardiovascular puzzle and a mainspring of disease-induced mortality. We performed this investigation to detect the role...
-
Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in...
Short hairpin RNAs are used to deplete circRNAs by targeting back-splicing junction sites. However, frequent discrepancies exist between shRNA-mediated circRNA knockdown and...
-
Minimal genome-wide human CRISPR-Cas9 library
CRISPR guide RNA libraries have been iteratively improved to provide increasingly efficient reagents, although their large size is a barrier for many applications. We design an...
-
Integrative analyses of TEDDY Omics data reveal lipid metabolism...
The Environmental Determinants of Diabetes in the Young is a prospective birth cohort designed to study type 1 diabetes by following children with high genetic risk. An...
-
Unraveling the roles of the reductant and free copper ions in LPMO kinetics
Lytic polysaccharide monooxygenases are monocopper enzymes that catalyze oxidative depolymerization of industrially relevant crystalline polysaccharides, such as cellulose, in...
-
Lignin intermediates lead to phenyl acid formation and microbial community...
Lignin intermediates resulting from lignocellulose degradation have been suspected to hinder anaerobic mineralisation of organic materials to biogas. Phenyl acids like...
-
AbbVie: Clinical Sales Representative - Temecula, CA
AbbVie: About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenge Temecula, CA...
-
Nitto BioPharma Inc.: Formulation Scientist NBPI033
Nitto BioPharma Inc.: Job Description Formulation Scientist Reporting To: Director, Platform Development Position Objective The incumbent will perf San Diego, CA, US ...